Key Segments
By Therapy Type
-
Enzyme Replacement Therapy (ERT)
-
Velaglucerase Alfa
-
Taliglucerase Alfa
-
Agalsidase Beta
-
Laronidase
-
Imiglucerase
-
Others (Idursulfase, Alglucosidase Alfa, Pegunigalsidase Alfa)
-
-
Substrate Reduction Therapy (SRT)
-
Eliglustat
-
Miglustat
-
Others (Lucerastat, Venglustat - in trials or early approval stages)
-
-
Gene Therapy
-
AAV-Based Gene Therapy (e.g., for Fabry and Gaucher)
-
Lentiviral Vector-Based Therapy
-
Others (CRISPR/Cas9-based gene editing therapies, Zinc Finger Nucleases (ZFNs))
-
-
Chaperone Therapy
-
Migalastat
-
Others (Ambroxol, Pyrimethamine)
-
By Application
-
Gaucher Disease
-
Fabry Disease
-
Pompe Disease
-
Mucopolysaccharidoses (MPS I, II, III, etc.)
-
Cystinosis
-
Niemann-Pick Disease
-
Others (Tay-Sachs, Sandhoff, Batten disease, Krabbe disease)
By Route of Administration
-
Intravenous (IV)
-
Oral
-
Subcutaneous
-
Others (Intrathecal administration for CNS-targeted therapies)
By End-User
-
Hospitals
-
Specialty Clinics
-
Homecare Settings
-
Others (Research Institutes, Compassionate Use Programs)
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
Egypt
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: Growth is driven by expanding diagnostic capabilities, increased R&D investments, regulatory incentives (like orphan drug designations), and a shift toward homecare and oral therapies. Regions like Asia Pacific are witnessing rapid growth due to improved awareness and healthcare access.
Ans: Key challenges include high treatment costs (often exceeding $300,000 annually), complex biomanufacturing, limited reimbursement in developing regions, and logistical barriers in administering intravenous therapies. Gene therapy scalability and regulatory scrutiny also remain hurdles.
Ans: Gaucher disease, Fabry disease, and Pompe disease are among the most treated due to higher prevalence, availability of approved therapies, and inclusion in newborn screening programs in regions like the U.S., Europe, and Japan.
Ans: Gene therapy offers the possibility of single-dose, long-term correction of enzyme deficiencies, reducing the need for lifelong infusions. Several candidates, such as REGENXBIO’s RGX-121 for MPS II and AVROBIO’s AVR-RD-02 for Gaucher disease, are showing promising clinical results and attracting regulatory support.
Ans: The primary treatment types include Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, and Chaperone Therapy. ERT remains the standard for several LSDs, while gene therapies and chaperone-based treatments are gaining momentum due to their potential for long-term efficacy and convenience.
Get in Touch
